InVivo Therapeutics Holdings Corp
NVIV
NVIV was delisted on the 12th of February, 2024.
9 hedge funds and large institutions have $252K invested in InVivo Therapeutics Holdings Corp in 2020 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.
13% more capital invested
Capital invested by funds: $224K → $252K (+$28K)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
10% less funds holding
Funds holding: 10 → 9 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$73K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
+$27K |
| 3 |
Two Sigma Investments
New York
|
+$24.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.61K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$55K |
| 2 |
NC
NewSquare Capital
Newtown Square,
Pennsylvania
|
-$2.81K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1.64K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.17K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $147K | +$73K | +1,874 | +101% |
|
|
WS
2
Wedbush Securities
Los Angeles,
California
| $72K | +$27K | +693 | +61% |
|
|
3
Two Sigma Investments
New York
| $25K | +$24.6K | +631 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $7K | +$2.61K | +67 | +68% |
|
5
BlackRock
New York
| $1K | – | – | – |
|
|
SM
6
Sabby Management
Miami Beach,
Florida
| – | -$55K | -1,306 | Closed |
|
|
NC
7
NewSquare Capital
Newtown Square,
Pennsylvania
| – | -$2.81K | -72 | -97% |
|
|
8
Bank of America
Charlotte,
North Carolina
| – | -$1.64K | -42 | -98% |
|
|
9
Osaic Holdings
Scottsdale,
Arizona
| – | -$1.17K | -30 | -97% |
|
NVIV Hedge Fund Activity: Q2 2020 in Review
9 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q2 2020, worth a combined $252K — up 13% from $224K a quarter earlier.
Fund positioning in NVIV was balanced in Q2 2020: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $73K. The largest seller was Sabby Management, exiting entirely with an estimated $55K sold.
- 9 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q2 2020, down from 10 in Q1 2020.
- Funds reported $252K of InVivo Therapeutics Holdings Corp stock for Q2 2020, up 13% quarter-over-quarter.
- 1 fund opened new InVivo Therapeutics Holdings Corp positions in Q2 2020 and 1 closed out, a net change of 0 holders.
- The largest InVivo Therapeutics Holdings Corp buyer in Q2 2020 was Renaissance Technologies, an estimated $73K added.
- The largest InVivo Therapeutics Holdings Corp seller in Q2 2020 was Sabby Management, an estimated $55K sold.
Based on aggregated 13F filings for Q2 2020.